What is HC Wainwright’s Forecast for DVAX Q2 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Dynavax Technologies in a report issued on Tuesday, January 14th. HC Wainwright analyst E. White expects that the biopharmaceutical company will post earnings of $0.08 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Separately, StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Performance

DVAX stock opened at $12.45 on Thursday. The firm has a 50 day moving average of $12.76 and a two-hundred day moving average of $11.67. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.30. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 95.78 and a beta of 1.34. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Hedge Funds Weigh In On Dynavax Technologies

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter worth $990,000. Nisa Investment Advisors LLC boosted its holdings in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares during the period. Ballentine Partners LLC acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at about $137,000. Nordea Investment Management AB increased its stake in shares of Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 1,457 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.